-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, BWnUuDoT1wCkn5UsWsF4BhXEK2ZT+HZVAVhzbISEWov3+0FqLbXyEr7412a6Mkc/ 1/ecp3ppgzRf9m5wsttkBQ== 0000884939-98-000014.txt : 19980804 0000884939-98-000014.hdr.sgml : 19980804 ACCESSION NUMBER: 0000884939-98-000014 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 19980803 ITEM INFORMATION: FILED AS OF DATE: 19980803 SROS: NASD FILER: COMPANY DATA: COMPANY CONFORMED NAME: SYNAPTIC PHARMACEUTICAL CORP CENTRAL INDEX KEY: 0000884939 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731] IRS NUMBER: 222859704 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: SEC FILE NUMBER: 000-27324 FILM NUMBER: 98676177 BUSINESS ADDRESS: STREET 1: 215 COLLEGE RD CITY: PARAMUS STATE: NJ ZIP: 07652 BUSINESS PHONE: 2012611331 8-K 1 SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 --------------------------- FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 3, 1998 SYNAPTIC PHARMACEUTICAL CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 0-27324 22-285-9704 (Commission File Number) (I.R.S. Employer Identification No.) 215 College Road Paramus, New Jersey 07652-1431 (Address of principal executive offices, including zip code) Registrant's telephone number, including area code: (201) 261-1331 Page 1 of 3 Pages Item 5. Other Events On August 3, 1998, the term of the Company's collaboration with Novartis, which was focused principally on the identification and development of neuropeptide Y drugs for the treatment of obesity and eating disorders, as well as cardiovascular disorders, expired in accordance with the terms of the Research and License Agreement dated as of August 4, 1994, as amended, and the Research and License Agreement dated as of May 31, 1996. In connection with the expiration of the collaboration, Novartis' obligation to provide the Company with funding to support a specified number of the Company's scientists terminated. Novartis continues to have a license under certain patent rights and to certain technology of the Company pursuant to the terms of the Research and License Agreements. Page 2 of 3 Pages SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: August 3, 1998 SYNAPTIC PHARMACEUTICAL CORPORATION (Registrant) By:/s/Kathleen P. Mullinix ------------------------------------------- Name: Kathleen P. Mullinix Title: Chairman, President and Chief Executive Officer Page 3 of 3 Pages -----END PRIVACY-ENHANCED MESSAGE-----